PIM1 and acute lymphoblastic leukemia: The use of JAK and PIM1 inhibitors in combination might warrant further study as increased levels of PIM1 were also reported in T-ALL patients harbouring IL7R, JAK3, and JAK1 mutations, not only in HOXA-mutated cases.90,94